{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:57:41Z","timestamp":1793653061325,"version":"4.5.1"},"reference-count":77,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>The increasing burden of diabetic kidney disease (DKD) has led to the discovery of novel therapies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This review aims to summarize the results of recent clinical trials that test the efficacy of potential therapies for DKD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A systematized narrative review was performed utilizing the PubMed, Embase (Ovid), CINAHL, and Cochrane databases (January 2010 to January 2021). The included trials assessed the efficacy of specific medications using renal endpoints in adult participants with type 1 or 2 diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifty-three trials were identified. Large, multinational, and high-powered trials investigating sodium-glucose cotransporter 2 (SGLT2) inhibitors demonstrated improved renal outcomes, even in patients with established DKD. Trials examining incretin-related therapies also showed some improvement in renal outcomes. Additionally, mineralocorticoid receptor antagonists exhibited potential with multiple improved renal outcomes in large trials, including those involving participants with established DKD. Atrasentan, baricitinib, ASP8232, PF-04634817, CCX140-B, atorvastatin, fenofibrate, probucol, doxycycline, vitamin D, omega-3 fatty acids, silymarin, turmeric, total glucosides of paeony, and tripterygium wilfordii Hook F extract were all associated with some improved renal endpoints but need further exploration. While bardoxolone methyl was associated with a decrease in albuminuria, high rates of cardiovascular adverse effects curtailed further exploration into this agent. Selonsertib, allopurinol, praliciguat, palosuran, benfotiamine, and diacerein were not associated with improved renal outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Trials have yielded promising results in the search for new therapies to manage DKD. SGLT2 inhibitors and incretin-related therapies have demonstrated benefit and were associated with improved cardiovascular outcomes. Mineralocorticoid receptor antagonists are another class of agents with increasing evidence of benefits.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab639","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T16:22:19Z","timestamp":1630340539000},"page":"e1-e24","source":"Crossref","is-referenced-by-count":18,"title":["Novel Therapies for Kidney Disease in People With Diabetes"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8509-2295","authenticated-orcid":false,"given":"Nayana","family":"Khurana","sequence":"first","affiliation":[{"name":"Melbourne Medical School, Department of Medicine, the University of Melbourne, Parkville, Victoria, 3010, Australia"},{"name":"Department of Endocrinology, Austin Health, Heidelberg, Victoria, 3084, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3928-9206","authenticated-orcid":false,"given":"Steven","family":"James","sequence":"additional","affiliation":[{"name":"School of Nursing, Midwifery and Paramedicine, the University of the Sunshine Coast, Petrie, Queensland, 4502, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda T","family":"Coughlan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Austin Health, Heidelberg, Victoria, 3084, Australia"},{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria, 3004, Australia"},{"name":"Department of Diabetes, Monash University, Central Clinical School, Alfred Medical Research Education Precinct, Melbourne, 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"MacIsaac","sequence":"additional","affiliation":[{"name":"Melbourne Medical School, Department of Medicine, the University of Melbourne, Parkville, Victoria, 3010, Australia"},{"name":"Department of Endocrinology & Diabetes, St Vincent\u2019s Hospital Melbourne, Fitzroy, Victoria, 3065, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2372-395X","authenticated-orcid":false,"given":"Elif I","family":"Ekinci","sequence":"additional","affiliation":[{"name":"Melbourne Medical School, Department of Medicine, the University of Melbourne, Parkville, Victoria, 3010, Australia"},{"name":"Department of Endocrinology, Austin Health, Heidelberg, Victoria, 3084, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"issue":"16","key":"2021121823152098700_CIT0001","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990-2010","volume":"370","author":"Gregg","year":"2014","journal-title":"N Engl J Med."},{"issue":"12","key":"2021121823152098700_CIT0002","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1A","key":"2021121823152098700_CIT0003","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1079\/PHN2003586","article-title":"Diet, nutrition and the prevention of type 2 diabetes","volume":"7","author":"Steyn","year":"2004","journal-title":"Public Health Nutr."},{"key":"2021121823152098700_CIT0004","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova","year":"2017","journal-title":"Diabetes Res Clin Pract."},{"issue":"9859","key":"2021121823152098700_CIT0005","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet."},{"issue":"5","key":"2021121823152098700_CIT0006","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2337\/dc12-0862","article-title":"Health care costs in people with diabetes and their association with glycemic control and kidney function","volume":"36","author":"McBrien","year":"2013","journal-title":"Diabetes Care."},{"issue":"2 Suppl 2","key":"2021121823152098700_CIT0007","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1053\/j.ajkd.2013.10.048","article-title":"Markers of and risk factors for the development and progression of diabetic kidney disease","volume":"63","author":"Macisaac","year":"2014","journal-title":"Am J Kidney Dis."},{"key":"2021121823152098700_CIT0008","article-title":"Two of a KinD (Kidneys in Diabetes): the burden of diabetic kidney disease and the cost effectiveness of screening people with type 2 diabetes for chronic kidney disease","author":"Deloitte Access Economics","year":"2011"},{"issue":"4s","key":"2021121823152098700_CIT0009","first-page":"S1","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","year":"2020","journal-title":"Kidney Int."},{"issue":"4","key":"2021121823152098700_CIT0010","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/20009666.2018.1500423","article-title":"Diabetic nephropathy: newer therapeutic perspectives","volume":"8","author":"Keri","year":"2018","journal-title":"J Community Hosp Intern Med Perspect."},{"issue":"1","key":"2021121823152098700_CIT0011","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3904\/kjim.2016.174","article-title":"New therapeutic agents in diabetic nephropathy","volume":"32","author":"Kim","year":"2017","journal-title":"Korean J Intern Med."},{"issue":"3","key":"2021121823152098700_CIT0012","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2337\/diaspect.28.3.167","article-title":"Novel therapies for diabetic kidney disease: storied past and forward paths","volume":"28","author":"Dieter","year":"2015","journal-title":"Diabetes Spectr."},{"issue":"9889","key":"2021121823152098700_CIT0013","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet."},{"issue":"2","key":"2021121823152098700_CIT0014","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation."},{"issue":"15","key":"2021121823152098700_CIT0015","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med."},{"key":"2021121823152098700_CIT0016","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"issue":"8","key":"2021121823152098700_CIT0017","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabet Endocrinol."},{"issue":"24","key":"2021121823152098700_CIT0018","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"issue":"7","key":"2021121823152098700_CIT0019","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"issue":"10","key":"2021121823152098700_CIT0020","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/dom.12936","article-title":"The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients","volume":"19","author":"Petrykiv","year":"2017","journal-title":"Diabetes Obes Metab."},{"issue":"10","key":"2021121823152098700_CIT0021","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1089\/dia.2018.0169","article-title":"Effect of canagliflozin on urinary albumin excretion in Japanese patients with type 2 diabetes mellitus and microalbuminuria: a pilot study","volume":"20","author":"Osonoi","year":"2018","journal-title":"Diabetes Technol Ther."},{"issue":"5","key":"2021121823152098700_CIT0022","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2169\/internalmedicine.3473-19","article-title":"Beneficial effects of ipragliflozin on the renal function and serum uric acid levels in Japanese patients with type 2 diabetes: a randomized, 12-week, open-label, active-controlled trial","volume":"59","author":"Tanaka","year":"2020","journal-title":"Intern Med."},{"issue":"4","key":"2021121823152098700_CIT0023","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med."},{"issue":"10","key":"2021121823152098700_CIT0024","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2337\/dc19-0937","article-title":"The impact of sotagliflozin on renal function, albuminuria, blood pressure, and hematocrit in adults with type 1 diabetes","volume":"42","author":"van Raalte","year":"2019","journal-title":"Diabetes Care."},{"issue":"2","key":"2021121823152098700_CIT0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med."},{"issue":"9","key":"2021121823152098700_CIT0026","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med."},{"issue":"19","key":"2021121823152098700_CIT0027","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"issue":"10193","key":"2021121823152098700_CIT0028","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"issue":"8","key":"2021121823152098700_CIT0029","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"2021121823152098700_CIT0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA."},{"issue":"11","key":"2021121823152098700_CIT0031","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/dom.13041","article-title":"Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial","volume":"19","author":"Groop","year":"2017","journal-title":"Diabetes Obesity Metab."},{"issue":"1","key":"2021121823152098700_CIT0032","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc16-0621","article-title":"Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial","volume":"40","author":"Mosenzon","year":"2017","journal-title":"Diabetes Care."},{"issue":"23","key":"2021121823152098700_CIT0033","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med."},{"issue":"9","key":"2021121823152098700_CIT0034","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA."},{"issue":"4","key":"2021121823152098700_CIT0035","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"Katayama","year":"2017","journal-title":"J Diabetes Complications."},{"issue":"12","key":"2021121823152098700_CIT0036","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"issue":"8","key":"2021121823152098700_CIT0037","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"2021121823152098700_CIT0038","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000327599","article-title":"Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD","volume":"33","author":"Pergola","year":"2011","journal-title":"Am J Nephrol."},{"issue":"4","key":"2021121823152098700_CIT0039","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N Engl J Med."},{"issue":"26","key":"2021121823152098700_CIT0040","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med."},{"issue":"10184","key":"2021121823152098700_CIT0041","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet."},{"issue":"5","key":"2021121823152098700_CIT0042","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J Am Soc Nephrol."},{"issue":"13-14","key":"2021121823152098700_CIT0043","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.lfs.2012.01.011","article-title":"Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD)","volume":"91","author":"Andress","year":"2012","journal-title":"Life Sci."},{"issue":"10","key":"2021121823152098700_CIT0044","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1681\/ASN.2018121231","article-title":"Effects of selonsertib in patients with diabetic kidney disease","volume":"30","author":"Chertow","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"11","key":"2021121823152098700_CIT0045","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","article-title":"JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial","volume":"33","author":"Tuttle","year":"2018","journal-title":"Nephrol Dial Transplant."},{"issue":"12","key":"2021121823152098700_CIT0046","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-8587(18)30289-4","article-title":"Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial","volume":"6","author":"de Zeeuw","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"26","key":"2021121823152098700_CIT0047","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","article-title":"Serum urate lowering with allopurinol and kidney function in type 1 diabetes","volume":"382","author":"Doria","year":"2020","journal-title":"N Engl J Med."},{"issue":"9","key":"2021121823152098700_CIT0048","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-8587(15)00261-2","article-title":"The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"2021121823152098700_CIT0049","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ekir.2018.07.010","article-title":"Effect of PF-04634817, an oral CCR2\/5 chemokine receptor antagonist, on albuminuria in adults with overt diabetic nephropathy","volume":"3","author":"Gale","year":"2018","journal-title":"Kidney Int Rep."},{"issue":"3","key":"2021121823152098700_CIT0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S2213-8587(14)70246-3","article-title":"Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"2021121823152098700_CIT0051","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1464-5491.2010.03139.x","article-title":"Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1)","volume":"28","author":"Rutter","year":"2011","journal-title":"Diabet Med."},{"issue":"2","key":"2021121823152098700_CIT0052","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the fenofibrate intervention and event lowering in diabetes (FIELD) study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia."},{"issue":"5","key":"2021121823152098700_CIT0053","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2337\/dc11-1811","article-title":"Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants","volume":"35","author":"Mychaleckyj","year":"2012","journal-title":"Diabetes Care."},{"issue":"5","key":"2021121823152098700_CIT0054","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/1753-0407.12347","article-title":"Telmisartan combined with probucol effectively reduces urinary protein in patients with type 2 diabetes: a randomized double-blind placebo-controlled multicenter clinical study","volume":"8","author":"Zhu","year":"2016","journal-title":"J Diabetes."},{"issue":"5","key":"2021121823152098700_CIT0055","doi-asserted-by":"crossref","first-page":"494","DOI":"10.5551\/jat.15263","article-title":"Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura study","volume":"20","author":"Endo","year":"2013","journal-title":"J Atheroscler Thromb."},{"issue":"Suppl 1","key":"2021121823152098700_CIT0056","article-title":"Phase 2 multicenter, randomized, double-blind, placebo-controlled trial to evaluate the soluble guanylate cyclase stimulator praliciguat in patients with diabetic kidney disease","volume":"69","author":"Hanrahan","year":"2020","journal-title":"Diabetes"},{"issue":"5","key":"2021121823152098700_CIT0057","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/HYPERTENSIONAHA.109.149559","article-title":"Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy","volume":"55","author":"Vogt","year":"2010","journal-title":"Hypertension."},{"issue":"8","key":"2021121823152098700_CIT0058","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3109\/0886022X.2010.502606","article-title":"Evaluation of role of doxycycline (a matrix metalloproteinase inhibitor) on renal functions in patients of diabetic nephropathy","volume":"32","author":"Aggarwal","year":"2010","journal-title":"Ren Fail."},{"issue":"19","key":"2021121823152098700_CIT0059","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1001\/jama.2019.17380","article-title":"Effect of vitamin D and omega-3 fatty acid supplementation on kidney function in patients with type 2 diabetes: a randomized clinical trial","volume":"322","author":"de Boer","year":"2019","journal-title":"JAMA."},{"issue":"7","key":"2021121823152098700_CIT0060","doi-asserted-by":"crossref","first-page":"e004740","DOI":"10.1161\/JAHA.116.004740","article-title":"Eicosapentaenoic and docosahexaenoic acids attenuate progression of albuminuria in patients with type 2 diabetes mellitus and coronary artery disease","volume":"6","author":"Elajami","year":"2017","journal-title":"J Am Heart Assoc."},{"key":"2021121823152098700_CIT0061","first-page":"S41","article-title":"An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease","volume":"95 Suppl 3","author":"Krairittichai","year":"2012","journal-title":"J Med Assoc Thai."},{"issue":"7","key":"2021121823152098700_CIT0062","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.2337\/dc09-2241","article-title":"A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy","volume":"33","author":"Alkhalaf","year":"2010","journal-title":"Diabetes Care."},{"issue":"12","key":"2021121823152098700_CIT0063","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s11255-017-1697-5","article-title":"Addition of silymarin to renin-angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial","volume":"49","author":"Voroneanu","year":"2017","journal-title":"Int Urol Nephrol."},{"issue":"6","key":"2021121823152098700_CIT0064","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1053\/j.ajkd.2012.06.005","article-title":"Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial","volume":"60","author":"Fallahzadeh","year":"2012","journal-title":"Am J Kidney Dis."},{"issue":"10","key":"2021121823152098700_CIT0065","doi-asserted-by":"crossref","first-page":"e0186554","DOI":"10.1371\/journal.pone.0186554","article-title":"Effect of diacerein on renal function and inflammatory cytokines in participants with type 2 diabetes mellitus and chronic kidney disease: a randomized controlled trial","volume":"12","author":"Piovesan","year":"2017","journal-title":"PLoS One."},{"issue":"5","key":"2021121823152098700_CIT0066","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/00365599.2011.585622","article-title":"Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-\u03b2 and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study","volume":"45","author":"Khajehdehi","year":"2011","journal-title":"Scand J Urol Nephrol."},{"issue":"11","key":"2021121823152098700_CIT0067","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s11255-016-1345-5","article-title":"Clinical study of total glucosides of paeony for the treatment of diabetic kidney disease in patients with diabetes mellitus","volume":"48","author":"Zhu","year":"2016","journal-title":"Int Urol Nephrol."},{"key":"2021121823152098700_CIT0068","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1479-5876-11-134","article-title":"Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial","volume":"11","author":"Ge","year":"2013","journal-title":"J Transl Med."},{"key":"2021121823152098700_CIT0069","doi-asserted-by":"crossref","first-page":"100486","DOI":"10.1016\/j.conctc.2019.100486","article-title":"Choosing primary endpoints for clinical trials of health care interventions","volume":"16","author":"McLeod","year":"2019","journal-title":"Contemp Clin Trials Commun."},{"issue":"1","key":"2021121823152098700_CIT0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12882-021-02381-3","article-title":"Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study","volume":"22","author":"Jeong","year":"2021","journal-title":"BMC Nephrol."},{"key":"2021121823152098700_CIT0071","volume-title":"National Diabetes Statistics Report, 2017.","author":"Centers for Disease Control and Prevention.","year":"2017"},{"issue":"1","key":"2021121823152098700_CIT0072","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/dc13-2112","article-title":"The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: overview","volume":"37","author":"Nathan","year":"2014","journal-title":"Diabetes Care."},{"issue":"5","key":"2021121823152098700_CIT0073","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2125.1999.00092.x","article-title":"The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes","volume":"48","author":"King","year":"1999","journal-title":"Br J Clin Pharmacol."},{"issue":"6","key":"2021121823152098700_CIT0074","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.kint.2016.09.010","article-title":"Management of patients with diabetes and CKD: conclusions from a \u201cKidney Disease: improving global outcomes\u201d (KDIGO) controversies conference","volume":"90","author":"Perkovic","year":"2016","journal-title":"Kidney Int."},{"issue":"1","key":"2021121823152098700_CIT0075","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13063-018-2616-5","article-title":"Intervention using vitamin D for elevated urinary albumin in type 2 diabetes mellitus (IDEAL-2 Study): study protocol for a randomised controlled trial","volume":"19","author":"Taheri","year":"2018","journal-title":"Trials."},{"key":"2021121823152098700_CIT0076","doi-asserted-by":"crossref","first-page":"105892","DOI":"10.1016\/j.cct.2019.105892","article-title":"A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1\/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: protocol and statistical considerations","volume":"90","author":"Reutens","year":"2020","journal-title":"Contemp Clin Trials."},{"key":"2021121823152098700_CIT0077","author":"Zoler","year":"2021"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab639\/40437292\/dgab639.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/1\/e1\/41819169\/dgab639.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/1\/e1\/41819169\/dgab639.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T23:19:32Z","timestamp":1639869572000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/1\/e1\/6359874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,8,30]]},"published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab639","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,8,30]]}}}